Skip to content
Peptide research

Exendin-4

Also known as Exenatide · Byetta · Bydureon
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
FDA-approved

What it is

A gut-hormone mimetic (basis of exenatide) that boosts insulin release and curbs appetite, used for blood sugar control and weight loss. The human case is strong: glycemic and weight benefits are well established, cardiovascular safety is moderately supported, but brain-protective claims stay speculative. GI upset is common, and rarer risks include pancreatitis and a thyroid tumor signal seen in animals. FDA-approved for diabetes; longevity use is off-label.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Glycemic control and HbA1c reduction in type 2 diabetes

    High

    FDA-approved indication, confirmed by large randomized trials including a 14,752-patient study.

  • Weight loss and metabolic improvement

    High

    Consistent 2 to 4 kg weight loss shown across multiple randomized controlled trials.

  • Pancreatic beta-cell preservation and regeneration

    Medium

    Human trials show better beta-cell function, but it fades quickly; regeneration is animal-only.

Evidence limits

Evidence Level
Level 1 — FDA Approved

Exendin-4/exenatide has the strongest clinical evidence base of almost any therapeutic peptide, anchored by FDA approval for type 2 diabetes based on multiple phase 3 RCTs and a 14,752-patient cardiovascular outcomes trial. Its glycemic efficacy (HbA1c reduction of 0.77-0.86%) and weight loss profile (1.6-2.8 kg over 30 weeks) are well-established. Cardiovascular safety was confirmed by the EXSCEL trial, with suggestive but non-significant MACE reduction and a nominally significant all-cause mortality benefit. The neuroprotection story is mixed: a promising phase 2 Parkinson's trial (Athauda 2017, n=62) showed motor improvement persisting after drug washout, but the phase 3 trial (Exenatide-PD3, 2025, n=194) reported no significant benefit, possibly due to insufficient brain penetration; The Lancet published an Expression of Concern about the paper in June 2026. Alzheimer's disease data remains at the pilot stage. Beta-cell regeneration evidence is robust preclinically but direct human demonstration is limited. Overall, exendin-4/exenatide is a clinically validated metabolic peptide with substantial but unproven potential beyond its approved diabetes indication.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Personal/family history of MTC (extended-release forms)

    Absolute

    Extended-release exenatide (Bydureon) carries MTC/MEN2 contraindication. Exendin-4 is the parent peptide.

  • Renal impairment

    Absolute

    Byetta is not recommended with CrCl below 30 mL/min or end-stage renal disease; Bydureon BCise is not recommended with eGFR below 45 mL/min/1.73 m² or end-stage renal disease. These are formulation-specific use restrictions, rather than an absolute contraindication shared by all exenatide products.

  • History of pancreatitis

    High

    FDA warning for exenatide: fatal hemorrhagic/necrotizing pancreatitis reported. Avoid with prior pancreatitis.

  • Severe gastroparesis

    High

    Exendin-4/exenatide slows gastric emptying. Patients with gastroparesis excluded from clinical trials.

General cautions

  • Pregnancy

    Absolute

    Animal studies showed reduced fetal growth. Discontinue before planned conception.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Gastrointestinal side effects (nausea, vomiting, diarrhea)

    High
  • Acute pancreatitis

    Moderate
  • Medullary thyroid carcinoma (MTC) — theoretical risk

    Theoretical
  • Hypoglycemia (when combined with sulfonylureas or insulin)

    High
  • Renal impairment and acute kidney injury

    Moderate
  • Injection site reactions (extended-release formulation)

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.